Author:
Ye Lixia,Chen Jieping,Fang Ting,Ma Rui,Wang Jianmei,Pan Xingqiang,Dong Hongjun,Xu Guozhang
Abstract
Abstract
Background
In China, enterovirus 71 (EV71) is the major etiological agents of hand foot mouth disease that poses severe risks to children’s health. Since 2015, three inactivated EV71 vaccines have been approved for use. Previous studies indicated the high willingness of EV71 vaccination in eastern China. However, few studies have assessed coverage and utilization patterns of EV71 vaccine in China.
Methods
Children born during 2012–2018 were sampled and their records were abstracted from Ningbo childhood immunization information management system. Descriptive statistics characterized the study population and assessed coverage and timeliness for EV71 vaccination. Simultaneous administration patterns as well as type of EV71 vaccine used were also evaluated. Bivariate and multivariable analysis was used to examine the relationship of socio-demographic characteristics with vaccination coverage and timeliness.
Results
Of 716,178 children living in Ningbo. One hundred seventy-two thousand two hundred thirty-six received EV71 vaccine with a coverage rate of 24.05% and only 8.61% received vaccination timely. 21.97% of children received the complete two dose EV71 series but only 6.49% completed timely. Vaccination coverage and timeliness increased significantly from 2012 birth cohort to 2018 birth cohort. Relatively higher coverage and timeliness were observed in resident children, Inner districts, high socioeconomic areas and large-scaled immunization clinics. Of 329,569 doses of EV71 vaccine, only 5853(1.78%) doses were administered at the same day as other vaccines.
Conclusions
There is a need for increasing EV71 vaccination coverage and timeliness as well as eliminating disparities among different populations. Our study highlights the importance of simultaneous administration to increasing coverage and timeliness of EV71 vaccination.
Funder
Ningbo Health Branding Subject Fund
the Science and Technology Planning Project of Ningbo
The Public Welfare Technology Application Research Funding Projects of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference37 articles.
1. World Health Organization Western Region. A guide to clinical management and public health response for hand, foot and mouth disease(HFMD). 2011.
2. Zheng Y, Jit M, Wu JT, Yang J, Leung K, Liao Q, et al. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12(9):e184266.
3. Koh WM, Badaruddin H, La H, Chen MI, Cook AR. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e442.
4. Goksugur N, Goksugur S. Images in clinical medicine. Hand, foot, and mouth disease. N Engl J Med. 2010;362(14):e49.
5. Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50):16–00824.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A multiplex one-step fluorescence quantitative differential diagnosis method for severe hand, foot and mouth disease caused by coxsackievirus A16;Journal of Virological Methods;2024-09
2. Analysis of the Impact of Inactivated A71 Vaccine on the Incidence of Hand–Foot–Mouth Disease in Pudong New Area, Shanghai;Vaccines;2024-08-26
3. Spatiotemporal Changes and Influencing Factors of Hand, Foot, and Mouth Disease in Guangzhou, China, From 2013 to 2022: Retrospective Analysis;JMIR Public Health and Surveillance;2024-08-02
4. Chinese parents’ intention to vaccinate their 0–5-year-old children with the EV-71 vaccine against hand, foot, and mouth disease and willingness-to-pay;Frontiers in Public Health;2024-03-07
5. Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers;Drug Design, Development and Therapy;2023-07